Dr. Russell Ware is the Director of Hematology and co-Executive Director of the Cancer and Blood Diseases Institute at Cincinnati Children’s Hospital Medical Center in Cincinnati, Ohio. Dr. Ware serves as Professor of Pediatrics and the Associate Director of the Global Health Center for the Department of Pediatrics. He holds the Marjory J. Johnson Endowed Chair of Hematology Translational Research.
Dr. Ware received his undergraduate degree in Chemistry from Furman University in Greenville, S.C., (1979) and both his medical degree (1983) and Ph.D. degree in Immunology (1991) from the Duke University School of Medicine. He completed his pediatric internship and residency training at Baylor College of Medicine and Texas Children's Hospital (1983-86) then returned to Duke for subspecialty training in Pediatric Hematology/Oncology (1986-89) before joining the faculty at Duke. In 2004, he served as the Lemuel Diggs Endowed Chair of Sickle Cell Disease and Chair of the Department of Hematology at St. Jude Children's Research Hospital in Memphis, Tennessee. In 2011, he became the Director of the Hematology Center and Director of the Center for Global Health at Baylor College of Medicine, before moving to Cincinnati in July 2013.
An accomplished physician-scientist, Ware has substantial NIH funding for several translational and clinical research projects in the field of sickle cell disease. His research interests include efficacy and effectiveness of hydroxyurea therapy, genetic modifiers of sickle cell disease, fetal hemoglobin induction, and genotoxicity. He is the Principal Investigator for several large trials in sickle cell disease, including TCD With Transfusions Changing to Hydroxyurea (TWiTCH), Sparing Conversion to Abnormal TCD Elevation (SCATE), Realizing Effectiveness Across Continents with Hydroxyurea (REACH), and the Uganda Sickle Surveillance Study (US3). He is co-Investigator on the HydroxyUrea STudy of Long-term Effects (HUSTLE), Long-term Effects of Erythrocyte Lysis (ELYSIS), BABY HUG Follow-up 2, and Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM). He has authored more than 230 scientific papers and 40 textbook chapters.